Effective Drug Regulation - A Multicountry Study and Annex 1: Guide for Data Collection to Assess Drug Regulatory Performance
(2002; 187 pages) View the PDF document
Table of Contents
View the documentACRONYMS
View the documentPREFACE
View the documentACKNOWLEDGEMENTS
View the documentEXECUTIVE SUMMARY
Open this folder and view contents1. DRUG REGULATION: OBJECTIVES AND ISSUES
Open this folder and view contents2. MULTICOUNTRY STUDY ON EFFECTIVE DRUG REGULATION
Open this folder and view contents3. PROFILE OF THE COUNTRIES
Open this folder and view contents4. REGULATORY FRAMEWORK
Open this folder and view contents5. REGULATORY CAPACITY
Open this folder and view contents6. LICENSING OF MANUFACTURING, DISTRIBUTION AND RETAIL SALE
Open this folder and view contents7. INSPECTION AND SURVEILLANCE
Open this folder and view contents8. PRODUCT ASSESSMENT AND REGISTRATION
Open this folder and view contents9. CONTROL OF DRUG PROMOTION AND ADVERTISING
Open this folder and view contents10. DRUG QUALITY CONTROL LABORATORY
Open this folder and view contents11. ASSESSING REGULATORY PERFORMANCE
Open this folder and view contents12. CONCLUSIONS AND RECOMMENDATIONS FOR EFFECTIVE DRUG REGULATION
Close this folderANNEX 1: GUIDE FOR DATA COLLECTION TO ASSESS DRUG REGULATORY PERFORMANCE
View the document1. Background information
View the document2. Drug regulation: overview
Close this folder3. Regulatory functions
View the document3.1 Licensing: persons, premises and practices
Close this folder3.2 Inspection and surveillance
View the document3.2.1 GMP inspection
View the document3.2.2 Inspection of distribution channels
View the document3.3 Product assessment and registration
View the document3.4 Adverse drug reaction monitoring
View the document3.5 Clinical trials
View the document3.6 Control of drug promotion and advertising
View the document3.7 Drug quality control laboratory
 
3.2.2 Inspection of distribution channels

Legal provisions

DIN1: What is title and date of enactment of the drug law/regulations and the article number of the provision requiring inspection of distribution channels?

________________________________________________________________

DIN2: Are there provisions in the drug law/regulations that define the powers and status of the inspectors?

Yes
No

DIN2.1: If yes, what are the powers of distribution channel inspectors?

________________________________________________________________

Organization

DIN3: Is there a distribution channel inspectorate?

Yes
No

DIN3.1: If yes, to whom does it report?

________________________________________________________________

DIN4: What is the relationship of the inspectorate with other bodies involved in drug regulation, particularly with the licensing unit?

________________________________________________________________

DIN5: Are there written guidelines for Good Distribution Practices (GDP)?

Yes
No

DIN5.1: If yes, give reference to title and date of publication of the guidelines:

________________________________________________________________

DIN6: Is there a job description pertaining to the duties and responsibilities of distribution channel inspectors?

Yes
No

DIN7: Are there inspection guidelines or SOP for inspectors of distribution channels?

Yes
No

DIN7.1: If yes, give reference to the date of publication of the guidelines or SOP:

________________________________________________________________

Human resources

DIN8: How many distribution channel inspectors are there in the whole country?

(a) Full-time ____________
(b) Part-time ____________

DIN9: Do inspectors of distribution channels receive training in distribution channel inspection?

Yes
No

DIN9.1: If yes, collect information on the qualifications, training and experience of the inspectors.

Qualification

Training offered

Experience

     
     

DIN10: What is the average net monthly salary of a distribution channel inspector compared to other categories indicated in the table?

Categories of staff

Salary (US$)

Inspector of distribution channels

 

Pharmacist working in a private retail pharmacy

 

Pharmacist working in a private hospital pharmacy

 

Pharmacist working in an import/wholesale distribution channel

 

Financing of distribution channel inspection

DIN11: Is there a specific budget for the distribution channel inspectorate?

Yes
No

DIN11.1: If yes, what was the budget of the distribution channel inspectorate during each of the last five years (US$):

Budget section

Year:

Year:

Year:

Year:

Year:

Capital budget

         

Salaries

         

Miscellaneous

         

Total

         

DIN11.2: What was the source of the budget in the last five years (answer yes/no)?

Source

Year:

Year:

Year:

Year:

Year:

Government

         

Fees

         

Other (specify):

         

DIN11.3: If the answer to DIN11 is no, what was the estimated expenditure of the distribution channel inspectorate in the last five years?

Estimated expenditure

Year:

Year:

Year:

Year:

Year:

US$

         

Local currency

         

DIN12: If fees are collected for inspection services, collect information on the types of inspection services on which fees have been levied and the amount of the fees charged.

Type of inspection services on which fees are levied

Fees charged (US$)

   
   
   

Activities

DIN13: Is responsibility for inspecting distribution channels decentralized?

Yes
No

DIN13.1: If yes, which body conducts inspections at the following levels?

Level of inspection

Inspecting body

Capital city (central)

 

Provincial/state/regional level

 

District level

 

Peripheral level

 

Customs warehouse or ports of entry

 

DIN14: What is the structural and functional relationship between the various inspection levels? Is there a reporting mechanism? Explain.

________________________________________________________________

DIN15: Are there planned inspections of distribution channels at the different levels?

Yes
No

DIN15.1: If yes, what is the number of planned inspections conducted, out of the total number of planned inspections targeted in each of the last five years? (If possible, give information about each level.)

Planned inspections

Year:

Year:

Year:

Year:

Year:

Planned inspections targeted

         

Planned inspections carried out

         

DIN16: What are the different enforcement measures (administrative or legal sanctions) taken against those who do not comply with the drug laws/regulations? Explain.

Administrative measures

Legal sanctions

   
   
   
   

DIN17: Give information below on the total number of violations registered and the number of the different enforcement measures taken in each of the last five years. (If other enforcement strategies are used, describe them.)

Violations and enforcement measures taken

Year:

Year:

Year:

Year:

Year:

Total number of violations

         

Warning letters issued

         

Fines

         

Imprisonment

         

Suspension of licence

         

Revocation of licence

         

Others (specify):

         

DIN18: Do the inspectors collect samples from distribution channels as part of planned quality surveillance activities?

Yes
No

DIN18.1: If yes, provide the following information for each of the last two years:

Samples collected in connection with:

Number of samples collected

Passed lab. test

Failed lab. test

 

Year:

Year:

Year:

Year:

Year:

Year:

Planned quality surveillance

           

Follow-up of complaints

           

Target testing/risk assessment

           

Others (specify):

           

Total

           

DIN18.2: If the testing is targeted against a limited list of products, what are the products and what criteria are used for selecting them? If there is a written sampling procedure for inspectors provide information:

________________________________________________________________

DIN19: What actions/sanctions have been taken against products that failed laboratory test in each of the last two years?

Year:

Actions taken

   
   

DIN20 If inspectors of distribution channels have found any of the following in their planned inspection activities in the last two years, provide information below:

Inspection finding

Number of cases found

 

Year:

Year:

Unlicensed pharmaceutical premises, (manufacturing, import, wholesale and retail)

   

Premises operated by nonprofessionals (not in accordance with the law)

   

Unrenewed/expired licences

   

Counterfeit products

   

Illegally imported products

   

Sale of expired products

   

Unregistered products

   

Products stored under improper conditions

   

Products not authorized to be sold in the establishment

   

Other (specify):

   

DIN21: Are quality requirements for drug products for export purposes the same as for those products for use within the country? Explain:

________________________________________________________________

Monitoring and evaluation

DIN22: Is there an audit and/or review system to examine the performance of inspectors and the inspectorate?

Yes
No

DIN22.1: If yes, indicate whether this is external, internal or both:

________________________________________________________________

DIN23: What actions have been taken as a result of the audits or reviews in the last five years?

 

Year:

Year:

Year:

Year:

Year:

Actions taken

         

DIN24: What are the main constraints, weaknesses or problems and the strengths of distribution channel inspection in the country?

Constraints/weaknesses/problems

Strengths

   
   
   

Indicators

1. Number of pharmaceutical distribution channels (importers, wholesalers, dispensing outlets) inspected, out of the total number of licensed pharmaceutical distribution channels (importers, wholesalers, dispensing outlets) in the country (indicate year).

2. Number of planned distribution channel inspections carried out, out of the total number of planned distribution channel inspections (indicate year).

3. Number of pharmaceutical distribution channels in violation of the regulations, out of the total number of licensed pharmaceutical distribution channels inspected (indicate year).

4. Number of samples collected, out of the total number of samples planned to be collected (indicate year).

5. Number of drug products beyond the expiry date, out of the total number of drug products collected from pharmaceutical distribution channels (indicate year).

If other strategies are used to prevent mistakes or improve compliance with the requirements of good distribution practice, describe them.

If there is any specific and important information that is not covered by the above questions, please provide additional information as appropriate.

to previous section to next section
 

Last updated: April 24, 2012